Cyclooxygenase-2 and epithelial growth factor receptor up-regulation during progression of Barrett's esophagus to adnocarcinoma

World Journal of Gastroenterology

Volumn 12, Issue 6, 2006, Pages 928-934

  Li, Yan ^a   Wo, John M ^a   Ray, Mukunda B ^a   Jones, Whitney ^a   Su, Ruifeng R ^a   Ellis, Susan ^a   Martin, Robert C G ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

Barrett's esophagus; Carcinogenesis; Cycloxgenase 2 (COX 2); Epithelial growth factor receptor (EGFR)

Indexed keywords

CYCLOOXYGENASE 2; GROWTH FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; CANCER GROWTH; CARCINOGENESIS; CELL STRUCTURE; COMPUTER SYSTEM; CONTROLLED STUDY; CORRELATION ANALYSIS; EPITHELIUM; ESOPHAGEAL ADENOCARCINOMA; FEMALE; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; UPREGULATION;

EID: 33645078633     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v12.i6.928     Document Type: Article

References (38)

1. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF Jr. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991; 265: 1287-1289
2. Pera M, Cameron AJ, Trastek VF, Carpenter HA, Zinsmeister AR. Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. Gastroenterology 1993; 104: 510-513
3. Farrow DC, Vaughan TL. Determinants of survival following the diagnosis of esophageal adenocarcinoma (United States). Cancer Causes Control 1996; 7: 322-327
4. Isolauri J, Luostarinen M, Isolauri E, Reinikainen P, Viljakka M, Keyrilainen O. Natural course of gastroesophageal reflux disease: 17-22 year follow-up of 60 patients. Am J Gastroenterol 1997; 92: 37-41
5. Altorki NK, Oliveria S, Schrump DS. Epidemiology and molecular biology of Barrett's adenocarcinoma. Semin Surg Oncol 1997; 13: 270-280
6. Geboes K. Barrett's esophagus: the metaplasia-dysplasia-carcinoma sequence: morphological aspects. Acta Gastroenterol Belg 2000; 63: 13-17
7. Jankowski JA, Wright NA, Meltzer SJ, Triadafilopoulos G, Geboes K, Casson AG, Kerr D, Young LS. Molecular evolution of the metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am J Pathol 1999; 154: 965-973
8. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70
9. Yarden Y. The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur J Cancer 2001; 37 Suppl 4: S3-S8
10. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995; 19: 183-232
11. Gately S, Li WW. Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy. Semin Oncol 2004; 31: 2-11
12. Evett GE, Xie W, Chipman JG, Robertson DL, Simmons DL. Prostaglandin G/H synthase isoenzyme 2 expression in fibroblasts: regulation by dexamethasone, mitogens, and oncogenes. Arch Biochem Biophys 1993; 306: 169-177
13. Lee SH, Soyoola E, Chanmugam P, Hart S, Sun W, Zhong H, Liou S, Simmons D, Hwang D. Selective expression of mitogen-inducible cyclooxygenase in macrophages stimulated with lipopolysaccharide. J Biol Chem 1992; 267: 25934-25938
14. Masferrer JL, Zweifel BS, Manning PT, Hauser SD, Leahy KM, Smith WG, Isakson PC, Seibert K. Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc Natl Acad Sci U S A. 1994; 91: 3228-3232
15. Funkhouser EM, Sharp GB. Aspirin and reduced risk of esophageal carcinoma. Cancer 1995; 76: 1116-1119
16. Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW Jr. Aspirin use and risk of fatal cancer. Cancer Res 1993; 53: 1322-1327
17. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995; 83: 493-501
18. Zimmermann KC, Sarbia M, Weber AA, Borchard F, Gabbert HE, Schror K. Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res 1999; 59:198-204
19. Yoshimoto T, Takahashi Y, Kinoshita T, Sakashita T, Inoue H, Tanabe T. Growth stimulation and epidermal growth factor receptor induction in cyclooxygenase-overexpressing human colon carcinoma cells. Adv Exp Med Biol 2002; 507: 403-407
20. Ranelletti FO, Almadori G, Rocca B, Ferrandina G, Ciabattoni G, Habib A, Galli J, Maggiano N, Gessi M, Lauriola L. Prognostic significance of cyclooxygenase-2 in laryngeal squamous cell carcinoma. Int J Cancer 2001; 95: 343-349
21. Tortora G, Caputo R, Damiano V, Melisi D, Bianco R, Fontanini G, Veneziani BM, De Placido S, Bianco AR, Ciardiello F. Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect. Clin Cancer Res 2003; 9: 1566-1572
22. Jankowski J, Hopwood D, Pringle R, Wormsley KG. Increased expression of epidermal growth factor receptors in Barrett's esophagus associated with alkaline reflux: a putative model for carcinogenesis. Am J Gastroenterol 1993; 88: 402-408
23. Reid BJ, Haggitt RC, Rubin CE, Roth G, Surawicz CM, Van Belle G, Lewin K, Weinstein WM, Antonioli DA, Goldman H. Observer variation in the diagnosis of dysplasia in Barrett's esophagus. Hum Pathol 1988; 19: 166-178
24. Haggitt RC. Barrett's esophagus, dysplasia, and adenocarcinoma. Hum Pathol 1994; 25: 982-993
25. Chen Z, Zhang X, Li M, Wang Z, Wieand HS, Grandis JR, Shin DM. Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck. Clin Cancer Res 2004; 10: 5930-5939
26. Marnett LJ. Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res 1992; 52: 5575-5589
27. Hla T, Ristimaki A, Appleby S, Barriocanal JG. Cyclooxygenase gene expression in inflammation and angiogenesis. Ann N Y Acad Sci 1993; 696: 197-204
28. Chung HY, Kim HJ, Kim JW, Yu BP. The inflammation hypothesis of aging: molecular modulation by calorie restriction. Ann N Y Acad Sci 2001; 928: 327-335
29. Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998; 38: 97-120
30. Hanif R, Pittas A, Feng Y, Koutsos MI, Qiao L, Staiano-Coico L, Shiff SI, Rigas B. Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem Pharmacol 1996; 52: 237-245
31. Goldberg Y, Nassif II, Pittas A, Tsai LL, Dynlacht BD, Rigas B, Shiff SJ. The anti-proliferatioe effect of sulindac and sulindac sulfide on HT-29 colon cancer cells: alterations in tumor suppressor and cell cycle-regulatory proteins. Oncogene 1996; 12: 893-901
32. Morham SG, Langenbach R, Loftin CD, Tiano HF, Vouloumanos N, Jennette JC, Mahler JF, Kluckman KD, Ledford A, Lee CA, Smithies O. Prostaglandin synthase 2 gene disrup tion causes severe renal pathology in the mouse. Cell 1995; 83: 473-482
33. Ullrich A, Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell 1990; 61: 203-212
34. Logan A. Intracrine regulation at the nucleus--a further mechanism of growth factor activity? J Endocrinol 1990; 125: 339-343
35. Sporn MB, Roberts AB. Autocrine secretion--10 years later. Ann Intern Med 1992; 117: 408-414
36. Aaronson SA. Growth factors and cancer. Science 1991; 254: 1146-1153
37. Sibilia M, Wagner EF. Strain-dependent epithelial defects in mice lacking the EGF receptor. Science 1995; 269: 234-238
38. Threadgill DW, Dlugosz AA, Hansen LA, Tennenbaum T, Lichti U, Yee D, LaMantia C, Mourton T, Herrup K, Harris RC. Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype. Science 1995; 269: 230-234